Hereditary Hemorrhagic Telangiectasia (HHT)Phase 1NCT07667413
Topical TOR-582 Treatment of Epistaxis in HHT
A Phase 1 study testing Topical sirolimus ointment in people with Hereditary Hemorrhagic Telangiectasia (HHT) and Epistaxis, run by Columbia University at 1 site in United States.
Trial summary
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
- What is being tested?
- Topical sirolimus ointment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2027to May 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older at the time of consent.
- Confirmed diagnosis of HHT, defined as meeting at least three of the four Curaçao criteria or preferably by genetic testing.
- Moderate nasal epistaxis represented by an Epistaxis Severity Score (ESS) between 3 and 8 at screening, average NOSE-HHT score of 1.01-2, with a self-reported history of at least four spontaneous nosebleeds per week and a cumulative weekly bleeding duration of at least 60 minutes.
- Stable nasal hygiene regimen and epistaxis-related medical management for at least 3 months prior to enrollment.
- Stable epistaxis pattern for at least 3 months prior to enrollment
- Adequate bone marrow function defined as:
Show all 13Show fewer
- Platelet count ≥ 100 × 10⁹/L (≥ 100,000/mm3)
- WBC count ≥ 2.5 × 10⁹/L at screening (≥ 2,500/mm3)
- Hgb ≥ 6g/dL with no transfusion in the prior 2 months
- INR ≤ 1.4 and activated partial thromboplastin time (aPTT) within institutional normal limits.
- Willingness to avoid initiation of other investigational or targeted therapeutic agents for epistaxis (including antiangiogenic or mTOR-modulating therapies) from the time of enrollment through study completion.
- Female participants of childbearing potential must have a negative pregnancy test at screening and agree to use effective contraception during the study and for 28 days following the final dose.
- Ability to comply with study procedures and follow-up visits, and capacity to provide written informed consent.
Who cannot join
- Any medical contraindication to systemic sirolimus use.
- Prior use of any mTOR inhibitor within the past 3 months.
- Endoscopic evaluation of nasal cavity (HES-based)
- Site: No numerical site exclusion
- Pattern: AVM-type vascular pattern (HES pattern score = 2).
- Crusting: Moderate to severe nasal crusting (HES crusting score ≥ 2).
Show all 26Show fewer
- Location: Telangiectasias isolated to the middle or posterior turbinates (HES location score ≥ 2).
- Perforation: Presence of a nasal septal perforation
- Surgical cautery or sclerotherapy within the past 3 months prior to enrollment
- Vascular embolization of nasal vasculature within the past 3 months prior to enrollment
- Clinically significant peripheral vascular disease or circulatory compromise.
- Current use of strong CYP3A4 modulators, including inhibitors (e.g., ketoconazole, clarithromycin) or inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort).
- Use of anti-angiogenic therapies within 30 days prior to screening (e.g., bevacizumab, pazopanib, thalidomide, lenalidomide).
- Use of illicit substances within the past 30 days, excluding marijuana.
- Use of anticoagulant, antiplatelet, or fibrinolytic medications within the past 30 days, except for low-dose aspirin (81 mg or less).
- Use of octreotide or systemic estrogen therapy within the past 30 days.
- Clinical laboratory evaluation:
- Renal dysfunction, defined as a serum creatinine level greater than 2.0 mg/dL.
- Hepatic impairment, indicated by total bilirubin above 2.0 mg/dL (or above 4.0 mg/dL in patients with a known diagnosis of Gilbert's syndrome) or liver transaminases exceeding three times the upper limit of normal.
- Known SMAD4 mutation with a history of significant gastrointestinal polyposis, unless colonoscopy within the past 18 months demonstrated either no polyps or ≤5 polyps judged to be clinically insignificant by a gastroenterologist.
- History of unprovoked venous thromboembolism, confirmed by imaging.
- Diagnosis of peripheral neuropathy as confirmed by neurologic evaluation.
- Documented hyperproliferative anemia (myelodysplastic syndrome, aplastic anemia, etc.).
- Current pregnancy or planned pregnancy within the next 6 months, or active breastfeeding.
- Concurrent participation in another interventional research study.
- Any condition, circumstance, language, or literacy limitation, that in the judgment of the investigator, would interfere with study participation or completion.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Columbia University Irving Medical Center
New York, New York, 10032
Jonathan B Overdevest, MD, PhD, (212) 305-6130, jo2566@cumc.columbia.edu
Jonathan B Overdevest, MD, PhD
About this study
Official title: A Phase I Trial of TOR-582, a Topical Sirolimus-based Treatment for Epistaxis in Adults With Hereditary Hemorrhagic Telangiectasia
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life. This study is testing a new nasal ointment called TOR-582, which contains sirolimus, to determine whether it can be used safely when applied inside the nose. Adults with HHT and frequent nosebleeds will be invited to participate. Participants will first complete one week of observation without treatment, followed by up to 12 weeks of applying the study ointment inside each nostril twice daily. Different participants will receive different strengths of the ointment so researchers can identify the safest dose. During the study, participants will attend study visits, complete questionnaires about their nosebleeds and quality of life, keep a daily nosebleed diary, undergo nasal examinations, and have blood tests to monitor safety and medication levels. The information gained from this study will help determine whether this topical treatment can be safely studied further and will support the development of a new, less invasive option for managing nosebleeds in people with HHT.
Read the detailed description
This is a Phase I single-center trial evaluating the safety, tolerability, and clinical activity of TOR-582 in adults with HHT-associated epistaxis. The study will include a Phase 1a Dose-Finding study and a preliminary Proof-of-Concept protocol. The study will employ a Bayesian Optimal Interval (BOIN) dose-finding design with accelerated titration. Phase 1a will commence with topical administration of the TOR-582 compound in the nasal cavity, starting with a 1% dose (.2mL, dose level 2) delivered twice daily for a 12-week dosing period.
Participants will complete a 1-week observational baseline period prior to initiation of treatment. The first 4 weeks of treatment will constitute the dose-limiting toxicity (DLT) evaluation period. Participants who complete the DLT evaluation period will continue treatment for an additional 8 weeks, for a total treatment duration of 12 weeks.
The study will enroll up to 27 participants. Patients who fail to complete the dosing regimen for at least 80% of assigned dosages in their assigned cycle of treatment for reasons other than DLT will be excluded from DLT evaluation and may be replaced.
- Being tested
- Topical sirolimus ointment
- Keywords
- Hereditary Hemorrhagic Telangiectasia, HHT, Epistaxis, Nosebleeds, Sirolimus, Rapamycin, Topical Sirolimus, Intranasal Therapy, Nasal Telangiectasia, Vascular Malformations, mTOR Inhibitor, Osler-Weber-Rendu Syndrome
- Medical subject headings
- Telangiectasia, Hereditary Hemorrhagic, Epistaxis, Vascular Malformations
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Topical sirolimus ointmentDrug
Also called TOR-582
The active formulation of TOR-582 incorporates sirolimus at concentrations of 5 mg/mL (0.5%), 10 mg/mL (1.0%), and 20 mg/mL (2.0%) along with other active ingredients in an oil-based carrier ointment. Ointment will be applied intranasally twice daily in 0.2mL applications using TC5-R - Topi-CLICK Micro® 5 mL devices, which dispense metered 0.05 mL doses.
Dose finding will begin at a dose of 10 mg/mL (1.0%). Doses will escalate sequentially across planned dose levels (Level 1: 5 mg/mL, Level 2: 10 mg/mL, Level 3: 20 mg/mL) as guided by the BOIN-AT design until the Maximum Tolerated Dose is identified.
| Study group | Role | What they receive |
|---|---|---|
| Dose Level 1 - 5 mg/mL (0.5%) | Experimental | Not described Receives: Drug: Topical sirolimus ointment |
| Dose Level 2 - 10 mg/mL (1.0%) | Experimental | Not described Receives: Drug: Topical sirolimus ointment |
| Dose Level 3 - 20 mg/mL (2.0%) | Experimental | Not described Receives: Drug: Topical sirolimus ointment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of dose-limiting toxicities (DLTs)
The occurrence of protocol-defined DLTs during the active treatment at each dose level, used to guide escalation/de-escalation decisions and determine the recommended Phase 1b dose. A DLT is defined as the occurrence of Grade 2 or higher AEs in greater than 25% of participants at a given dose level, or more than one Grade 3 or higher AE at any point in the trial.
Measured: From enrollment through the first 4 weeks of treatment for each cohort (the DLT evaluation window)
Number of participants with treatment-emergent adverse events (AEs)
The aggregate count of participants experiencing AEs across the entire 12-week treatment period.
Measured: From enrollment through end of treatment, typically at 12 weeks.
Severity of treatment-emergent adverse events, graded according to the NCI CTCAE v6.0.
The highest severity grade of clinical AEs experienced by each participant. The CTCAE scale ranges from Grade 1 (Mild) to Grade 5 (Death), where higher grades indicate greater clinical severity.
Measured: From enrollment through the first 4 weeks of treatment for each cohort (the DLT evaluation window)
Whole blood sirolimus trough concentrations
Measured: Assessed at baseline, after 4 weeks of treatment, and at the end of treatment at 12 weeks
Secondary outcomes (26)
Epistaxis severity, measured by the Epistaxis Severity Score (ESS)
Trends in the ESS at baseline and during and after treatment will quantify changes in bleeding burden. The ESS ranges from 0 to 10, with higher scores indicating greater severity.
Measured: Assessed at baseline, initiation of treatment, every 4 weeks during treatment, and at the end of treatment, typically at 12 weeks
Patient-reported frequency of epistaxis episodes
Recorded as frequency of entries in the Cure HHT Diary and averaged over 28-day periods to supplement the ESS.
Measured: Recorded daily from beginning of screening period through end of treatment, typically at 12 weeks.
Patient-reported duration of epistaxis episodes
Recorded via Cure HHT Diary on a six-tiered scale, with a minimum duration of <1 minute and a maximum of >60 minutes.
Measured: Recorded daily from beginning of screening period through end of treatment, typically at 12 weeks.
Patient-reported intensity of epistaxis episodes
Recorded via Cure HHT Diary on a scale ranging from 1 ("spotting") to 6 ("gushing") and averaged over 28-day periods to supplement the ESS. Higher scores indicate greater intensity.
Measured: Recorded daily from beginning of screening period through end of treatment, typically at 12 weeks.
Patient-reported overall severity of epistaxis episodes
Recorded via Cure HHT Diary on a scale ranging from 1 to 10 and averaged over 28-day periods to supplement the ESS. Higher scores indicate greater overall severity.
Measured: Recorded daily from beginning of screening period through end of treatment, typically at 12 weeks.
Clinical Global Impression - Severity (CGI-S) score, adapted for epistaxis
The subjective assessment of nosebleed severity, as measured using adapted items from the Clinical Global Impression (CGI) scale. Participants will be asked: "Overall, how would you rate your nosebleeds now?", with response options ranging from 1 ("Excellent - no nosebleeds") to 6 ("Very Poor - nosebleeds are constant or severely disruptive"). Higher scores indicate greater severity.
Measured: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks).
Clinical Global Impression - Improvement (CGI-I) score, adapted for epistaxis.
Clinical Global Impression - Improvement (CGI-I) score, adapted for epistaxis. The subjective assessment of treatment-related change in nosebleed severity, as measured using adapted items from the Clinical Global Impression (CGI) scale. Participants will be asked: "Overall, how would you rate your nosebleeds since starting the treatment with this ointment?", with response options ranging from 1 ("much better") to 7 ("much worse"). Higher scores indicate less improvement.
Measured: Every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Clinical Global Impression - Quality of Life (CGI-QoL) score, adapted for epistaxis.
The subjective assessment of the impact of nosebleeds on quality of life, as measured using adapted items from the Clinical Global Impression (CGI) scale. Participants will be asked: "Overall, how would you rate how much your nosebleeds affect your overall quality of life?", with response options ranging from 1 ("not at all") to 6 ("extreme"). Higher scores indicate greater impact on quality of life.
Measured: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
HHT-Specific Quality of Life (QoL)
Participants will complete a 4-item, validated HHT-specific QoL questionnaire designed to assess the functional impact of HHT-related epistaxis. Each item is scored from 0 (never) to 4 (very often), yielding a total score ranging from 0 (no limitations) to 16 (severe limitations). Higher scores indicate more severe limitations of quality of life.
Measured: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Modified QoL-HHT score
The QoL-HHT is a 24-item, disease-specific questionnaire that quantifies multi-faceted impact of HHT on individual patient lives. Each statement is scored on a 5-point Likert scale ranging from 1 = "strongly disagree" to 5 = "strongly agree." Items are categorized into six validated domains: physical limitations (PL), social relationships (SR), concern about bleeding (CAB), relationship with the medical profession (RMP), experience of symptoms (ES), and concern about disease evolution (ED). This trial will use a modified 8-item QoL-HHT score by selecting specified items focused particularly on the overall burden of epistaxis in each participant's daily life, with higher scores indicating greater burden.
Measured: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Satisfaction with Social Roles and Activities, measured by PROMIS® Short Form 8a v2.0
This is one of three short-form questionnaires from the NIH Patient-Reported Outcomes Measurement Information System (PROMIS®) which will be used to evaluate the impact of treatment on overall well-being and functioning. Each form yields a standardized T-score generated via the PROMIS® scoring engine, allowing comparison to a normative population (mean = 50, SD = 10). This 8-item measure evaluates satisfaction with social participation and daily responsibilities. Items include statements such as: "I am satisfied with my ability to do regular daily activities." Higher T-scores indicate greater satisfaction with social roles.
Measured: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Depression, measured by PROMIS® Short Form 8b v1.0
This is one of three short-form questionnaires from the NIH Patient-Reported Outcomes Measurement Information System (PROMIS®) which will be used to evaluate the impact of treatment on overall well-being and functioning. Each form yields a standardized T-score generated via the PROMIS® scoring engine, allowing comparison to a normative population (mean = 50, SD = 10). This 8-item form assesses depressive symptoms experienced in the past 7 days, including feelings of sadness, hopelessness, and worthlessness. Higher T-scores indicate more severe depressive symptoms.
Measured: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Fatigue, measured by PROMIS® Short Form 6a v1.0
This is one of three short-form questionnaires from the NIH Patient-Reported Outcomes Measurement Information System (PROMIS®) which will be usde to evaluate the impact of treatment on overall well-being and functioning. Each form yields a standardized T-score generated via the PROMIS® scoring engine, allowing comparison to a normative population (mean = 50, SD = 10). This 6-item questionnaire measures fatigue severity and its interference with physical and social functioning. Items include: "How fatigued were you on average?" Higher T-scores reflect more severe fatigue.
Measured: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
EQ-5D Visual Analogue Scale (EQ-VAS)
The EuroQol Visual Analogue Scale is a validated, standardized instrument developed by the EuroQol Group to capture a participant's self-rated health status. Participants indicate their current overall health on a vertical scale ranging from 0 ("worst imaginable health") to 100 ("best imaginable health"), generating a single index value of health-related quality of life. Higher scores indicate greater health-related quality of life.
Measured: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Patient Satisfaction with Treatment
Participants will be asked, "Overall, how satisfied are you with the ointment?", with answer choices ranging from 1 ("completely dissatisfied") to 7 ("completely satisfied"). Higher scores indicate greater satisfaction.
Measured: At end of treatment, typically at 12 weeks
Perceived treatment benefit and satisfaction, measured by Modified TTAQ.
Topical Therapy Adherence Questionnaire (TTAQ) and companion Patient Preference Questionnaire (PPQ) were developed by Zschocke et al. to identify patient- and treatment-related factors that influence adherence to topical therapies. This trial uses a modified 19-item version of the TTAQ, focusing specifically on the Treatment Satisfaction and Benefits to Patient domains and curated to minimize respondent burden and align with the use of topical sirolimus in the nasal mucosa. Participants rate their agreement with each item on a 4-point Likert scale, ranging from 0 ("strongly disagree") to 3 ("strongly agree"), where higher scores indicate greater treatment satisfaction and benefit to patient.
Measured: At end of treatment (typically at 12 weeks)
Perceived treatment benefit and satisfaction, measured by Modified PPQ
The Topical Therapy Adherence Questionnaire (TTAQ) and companion Patient Preference Questionnaire (PPQ) were developed by Zschocke et al. to identify patient- and treatment-related factors that influence adherence to topical therapies. This trial uses a modified, 6-item version of the PPQ, focusing specifically on the Treatment Satisfaction and Benefits to Patient domains and curated to minimize respondent burden and align with our use of topical sirolimus in the nasal mucosa. Participants rate their agreement with each item on a 4-point Likert scale, ranging from 0 ("strongly disagree") to 3 ("strongly agree"), where higher scores indicate greater treatment satisfaction and benefit to patient.
Measured: At end of treatment (typically at 12 weeks)
Hematologic Support Score (HSS)
The HSS is a composite measure that combines the assessment of red blood cell transfusion and iron infusion into a single endpoint, enabling evaluation over time. A higher number indicates greater transfusion/infusion burden.
Measured: During screening and at end of treatment, typically at 12 weeks
Hematologic Impact Score (HIS)
The HIS assesses the total hematologic impact over a reference time frame by accounting for changes in hemoglobin and HSS during that period (a higher number indicates greater improvement in hematologic status).
Measured: During screening and at end of treatment, typically at 12 weeks
Mean change in hemoglobin concentration from baseline
Measured via standard automated complete blood count (CBC).
Measured: During screening and at the end of treatment, typically at 12 weeks
Mean change in hematocrit from baseline
Measured via standard automated complete blood count (CBC).
Measured: During screening and at the end of treatment, typically at 12 weeks
Mean change in mean corpuscular volume (MCV) from baseline
Measured via standard automated complete blood count (CBC).
Measured: During screening and at the end of treatment, typically at 12 weeks
Mean change in serum ferritin from baseline
Measured via standard iron panel.
Measured: During screening and at the end of treatment, typically at 12 weeks
Mean change in transferrin saturation from baseline
Measured via standard iron panel.
Measured: During screening and at the end of treatment, typically at 12 weeks
Number of red blood cell transfusions and parenteral iron administrations during treatment period
Measured via patient reporting.
Measured: Assessed during screening and at end of treatment, typically at 12 weeks
Endoscopic Disease Activity
Change in nasal telangiectasia severity, assessed by a modified HHT Endoscopy Score (HES). The HES is a clinician-administered scoring system used to assess the severity of nasal telangiectasias during endoscopic evaluation. For this study, five domains will be used: number of sites involved, vascular pattern, crusting, lesion location, and septal perforation. Each is scored from 0 to 3, with higher scores indicating more extensive disease.
Measured: Assessed during screening, after first 4 weeks of treatment (end of DLT evaluation period), and end of treatment (typically at 12 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2026
- Study startMar 2027 (estimated)
- Primary completionMay 2028 (estimated)
- Study completionMay 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hereditary Hemorrhagic Telangiectasia (HHT)Studies of the same condition, open and under way.
- More trials run by Columbia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- This is an open-label, single-center, sequential dose-escalation Phase 1a study evaluating the safety, tolerability, and preliminary efficacy of intranasal topical sirolimus ointment in adults with hereditary hemorrhagic telangiectasia (HHT)-associated epistaxis. Participants will be enrolled into escalating dose cohorts and treated for up to 12 weeks with safety monitoring throughout the study period.
- Masking
- None (open label)
- Enrolment
- 27 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Columbia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jonathan B Overdevest, Columbia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07667413
- Sponsor's protocol ID
- AAAV9649
- Status last verified
- Nov 2026
- First submitted
- 18 Jun 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be publicly shared due to the small sample size and potential risk of participant re-identification in this rare disease population.
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Trial of TOR-582, a Topical Sirolimus-based Treatment for Epistaxis in Adults With Hereditary Hemorrhagic Telangiectasia
- ClinicalTrials.gov ID
- NCT07667413
- Acronym / sponsor ID
- AAAV9649
- Keywords
- Hereditary Hemorrhagic Telangiectasia, HHT, Epistaxis, Nosebleeds, Sirolimus, Rapamycin, Topical Sirolimus, Intranasal Therapy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 27 participants (estimated)
- Lead sponsor
- Columbia UniversityUniversity, hospital or other
- Study start
- Mar 2027 (estimated)
- Primary completion
- May 2028 (estimated)
- Study completion
- May 2028 (estimated)
- First posted
- 25 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life. This study is testing a new nasal ointment called TOR-582, which contains sirolimus, to determine whether it can be used safely when applied inside the nose. Adults with HHT and frequent nosebleeds will be invited to participate. Participants will first complete one week of observation without treatment, followed by up to 12 weeks of applying the study ointment inside each nostril twice daily. Different participants will receive different strengths of the ointment so researchers can identify the safest dose. During the study, participants will attend study visits, complete questionnaires about their nosebleeds and quality of life, keep a daily nosebleed diary, undergo nasal examinations, and have blood tests to monitor safety and medication levels. The information gained from this study will help determine whether this topical treatment can be safely studied further and will support the development of a new, less invasive option for managing nosebleeds in people with HHT.
Detailed description
This is a Phase I single-center trial evaluating the safety, tolerability, and clinical activity of TOR-582 in adults with HHT-associated epistaxis. The study will include a Phase 1a Dose-Finding study and a preliminary Proof-of-Concept protocol. The study will employ a Bayesian Optimal Interval (BOIN) dose-finding design with accelerated titration. Phase 1a will commence with topical administration of the TOR-582 compound in the nasal cavity, starting with a 1% dose (.2mL, dose level 2) delivered twice daily for a 12-week dosing period.
Participants will complete a 1-week observational baseline period prior to initiation of treatment. The first 4 weeks of treatment will constitute the dose-limiting toxicity (DLT) evaluation period. Participants who complete the DLT evaluation period will continue treatment for an additional 8 weeks, for a total treatment duration of 12 weeks.
The study will enroll up to 27 participants. Patients who fail to complete the dosing regimen for at least 80% of assigned dosages in their assigned cycle of treatment for reasons other than DLT will be excluded from DLT evaluation and may be replaced.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- This is an open-label, single-center, sequential dose-escalation Phase 1a study evaluating the safety, tolerability, and preliminary efficacy of intranasal topical sirolimus ointment in adults with hereditary hemorrhagic telangiectasia (HHT)-associated epistaxis. Participants will be enrolled into escalating dose cohorts and treated for up to 12 weeks with safety monitoring throughout the study period.
| Arm | Type | Receives |
|---|---|---|
| Dose Level 1 - 5 mg/mL (0.5%) | Experimental | Drug: Topical sirolimus ointment |
| Dose Level 2 - 10 mg/mL (1.0%) | Experimental | Drug: Topical sirolimus ointment |
| Dose Level 3 - 20 mg/mL (2.0%) | Experimental | Drug: Topical sirolimus ointment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Age 18 years or older at the time of consent.
- Confirmed diagnosis of HHT, defined as meeting at least three of the four Curaçao criteria or preferably by genetic testing.
- Moderate nasal epistaxis represented by an Epistaxis Severity Score (ESS) between 3 and 8 at screening, average NOSE-HHT score of 1.01-2, with a self-reported history of at least four spontaneous nosebleeds per week and a cumulative weekly bleeding duration of at least 60 minutes.
- Stable nasal hygiene regimen and epistaxis-related medical management for at least 3 months prior to enrollment.
- Stable epistaxis pattern for at least 3 months prior to enrollment
Key exclusion criteria (26 listed)
- Any medical contraindication to systemic sirolimus use.
- Prior use of any mTOR inhibitor within the past 3 months.
- Endoscopic evaluation of nasal cavity (HES-based)
- Surgical cautery or sclerotherapy within the past 3 months prior to enrollment
- Vascular embolization of nasal vasculature within the past 3 months prior to enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Topical sirolimus ointmentAlso: TOR-582The active formulation of TOR-582 incorporates sirolimus at concentrations of 5 mg/mL (0.5%), 10 mg/mL (1.0%), and 20 mg/mL (2.0%) along with other active ingredients in an oil-based carrier ointment. Ointment will be applied intranasally twice daily in 0.2mL applications using TC5-R - Topi-CLICK Micro® 5 mL devices, which dispense metered 0.05 mL doses. Dose finding will begin at a dose of 10 mg/mL (1.0%). Doses will escalate sequentially across planned dose levels (Level 1: 5 mg/mL, Level 2: 10 mg/mL, Level 3: 20 mg/mL) as guided by the BOIN-AT design until the Maximum Tolerated Dose is identified. | Drug | Dose Level 1 - 5 mg/mL (0.5%), Dose Level 2 - 10 mg/mL (1.0%), Dose Level 3 - 20 mg/mL (2.0%) |
Primary outcome
Incidence of dose-limiting toxicities (DLTs)
Time frame: From enrollment through the first 4 weeks of treatment for each cohort (the DLT evaluation window)
The occurrence of protocol-defined DLTs during the active treatment at each dose level, used to guide escalation/de-escalation decisions and determine the recommended Phase 1b dose. A DLT is defined as the occurrence of Grade 2 or higher AEs in greater than 25% of participants at a given dose level, or more than one Grade 3 or higher AE at any point in the trial.
Number of participants with treatment-emergent adverse events (AEs)
Time frame: From enrollment through end of treatment, typically at 12 weeks.
The aggregate count of participants experiencing AEs across the entire 12-week treatment period.
Severity of treatment-emergent adverse events, graded according to the NCI CTCAE v6.0.
Time frame: From enrollment through the first 4 weeks of treatment for each cohort (the DLT evaluation window)
The highest severity grade of clinical AEs experienced by each participant. The CTCAE scale ranges from Grade 1 (Mild) to Grade 5 (Death), where higher grades indicate greater clinical severity.
Whole blood sirolimus trough concentrations
Time frame: Assessed at baseline, after 4 weeks of treatment, and at the end of treatment at 12 weeks
26 secondary outcomes
Epistaxis severity, measured by the Epistaxis Severity Score (ESS)
Time frame: Assessed at baseline, initiation of treatment, every 4 weeks during treatment, and at the end of treatment, typically at 12 weeks
Patient-reported frequency of epistaxis episodes
Time frame: Recorded daily from beginning of screening period through end of treatment, typically at 12 weeks.
Patient-reported duration of epistaxis episodes
Time frame: Recorded daily from beginning of screening period through end of treatment, typically at 12 weeks.
Patient-reported intensity of epistaxis episodes
Time frame: Recorded daily from beginning of screening period through end of treatment, typically at 12 weeks.
Patient-reported overall severity of epistaxis episodes
Time frame: Recorded daily from beginning of screening period through end of treatment, typically at 12 weeks.
Clinical Global Impression - Severity (CGI-S) score, adapted for epistaxis
Time frame: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks).
Clinical Global Impression - Improvement (CGI-I) score, adapted for epistaxis.
Time frame: Every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Clinical Global Impression - Quality of Life (CGI-QoL) score, adapted for epistaxis.
Time frame: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
HHT-Specific Quality of Life (QoL)
Time frame: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Modified QoL-HHT score
Time frame: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Satisfaction with Social Roles and Activities, measured by PROMIS® Short Form 8a v2.0
Time frame: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Depression, measured by PROMIS® Short Form 8b v1.0
Time frame: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Fatigue, measured by PROMIS® Short Form 6a v1.0
Time frame: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
EQ-5D Visual Analogue Scale (EQ-VAS)
Time frame: At baseline, initiation of treatment, every 4 weeks during treatment, and at end of treatment (typically at 12 weeks)
Patient Satisfaction with Treatment
Time frame: At end of treatment, typically at 12 weeks
Perceived treatment benefit and satisfaction, measured by Modified TTAQ.
Time frame: At end of treatment (typically at 12 weeks)
Perceived treatment benefit and satisfaction, measured by Modified PPQ
Time frame: At end of treatment (typically at 12 weeks)
Hematologic Support Score (HSS)
Time frame: During screening and at end of treatment, typically at 12 weeks
Hematologic Impact Score (HIS)
Time frame: During screening and at end of treatment, typically at 12 weeks
Mean change in hemoglobin concentration from baseline
Time frame: During screening and at the end of treatment, typically at 12 weeks
Mean change in hematocrit from baseline
Time frame: During screening and at the end of treatment, typically at 12 weeks
Mean change in mean corpuscular volume (MCV) from baseline
Time frame: During screening and at the end of treatment, typically at 12 weeks
Mean change in serum ferritin from baseline
Time frame: During screening and at the end of treatment, typically at 12 weeks
Mean change in transferrin saturation from baseline
Time frame: During screening and at the end of treatment, typically at 12 weeks
Number of red blood cell transfusions and parenteral iron administrations during treatment period
Time frame: Assessed during screening and at end of treatment, typically at 12 weeks
Endoscopic Disease Activity
Time frame: Assessed during screening, after first 4 weeks of treatment (end of DLT evaluation period), and end of treatment (typically at 12 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be publicly shared due to the small sample size and potential risk of participant re-identification in this rare disease population.
Related trials for Hereditary Hemorrhagic Telangiectasia (HHT)
RecruitingPhase 1/2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
RecruitingObservational study
Quality of Life in Pediatric Participants With HHT
Hereditary Haemorrhagic Telangiectasia (HHT)
Not yet recruitingObservational study
Prevalence of Obstructive Sleep Apnea in HHT and HHT-specific Challenges in OSA-therapy - a Retrospective Cohort Study
Hereditary Hemorrhagic Telangiectasia (HHT), Obstructive Sleep Apnea (OSA)
Active, not recruitingPhase 1/2
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia
Not yet recruitingPhase 1
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Topical sirolimus ointment in people with Hereditary Hemorrhagic Telangiectasia (HHT) and Epistaxis, run by Columbia University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jonathan B Overdevest, MD, PhD (212-305-6130, jo2566@cumc.columbia.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of dose-limiting toxicities (DLTs) (time frame: From enrollment through the first 4 weeks of treatment for each cohort (the DLT evaluation window)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.